



Enzon Pharmaceuticals Inc.  
Investor Relations Department  
20 Kingsbridge Road  
Attn: Accounts Payable  
Piscataway, NJ 08854  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### OT: ENZN <sup>1</sup>

Last Trade: 0.27

Trade Time: 3:55 PM ET  
Oct 17, 2017

Change: 0.03   
(12.185%)

Day Range 0.24 - 0.29

52-Week Range 0.22 - 0.50

Volume 185,249

Market Cap.  
(\$M) 11.807

Shares Out (M) 44.220

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron®, Sylatron®, Macugen® and CIMZIA®. ... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*May 1, 2014*  
[Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards](#)

*Apr 23, 2013*  
[Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces \\$1.60 Special Dividend and Periodic Royalty Dividends](#)

*Mar 18, 2013*  
[Enzon Reports Fourth Quarter and Full Year 2012 Results](#)

*Dec 17, 2012*  
[Enzon to Review Asset Sales, Sale of the Company](#)

*Nov 29, 2012*  
[Enzon Announces Special Dividend](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

*Mar 24, 2017*  
[Annual Report \(10-K\)](#)

*May 12, 2017*  
[Definitive Proxy Statement](#)

*Aug 10, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 11, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 10, 2016*  
[Quarterly Report \(10-Q\)](#)